Table 2.
Cost Comparison for Non-Medication Materials: Using the PhaSeal® CSTD Versus Conventional Needle-Syringe Methods (Hypothetical Scenario).
| Drugs | Number of preparations | Costs | (MYR) | Cost differences (MYR)c | Cost differences (%)c |
|---|---|---|---|---|---|
| With CSTDa | Without CSTDb | ||||
| Bendamustine | 1 | 68.5 | 22.0 | 46.5 | 211.5 |
| Bleomycin | 24 | 1,153.3 | 373.5 | 779.8 | 208.8 |
| Bortezomib | 36 | 1,104.8 | 120.6 | 984.2 | 816.1 |
| Carboplatin | 85 | 4,119.3 | 783.5 | 3,335.8 | 425.8 |
| Cisplatin | 113 | 6,069.0 | 1974 | 4,095.0 | 207.4 |
| Cyclophosphamide | 196 | 7,594.6 | 2,334 | 5,260.6 | 225.4 |
| Cytarabine | 166 | 7,566.0 | 2,516.6 | 5,049.4 | 200.6 |
| Dacarbazine | 17 | 1,742.0 | 315.0 | 1,427.0 | 453.0 |
| Daunorubicin | 6 | 608.3 | 230.5 | 377.8 | 163.9 |
| Docetaxel | 36 | 1,963.5 | 667.6 | 1,295.9 | 194.1 |
| Doxorubicin | 95 | 2,826.5 | 1,269.5 | 1,557.0 | 122.6 |
| Epirubicin | 82 | 4,887.6 | 1,703.5 | 3,184.1 | 186.9 |
| Etoposide | 83 | 3,394.4 | 1,087.5 | 2,306.9 | 212.1 |
| Fluorouracil | 765 | 24,523.8 | 6,819.0 | 17,704.8 | 259.6 |
| Gemcitabine | 92 | 5012.6 | 1,764.0 | 3,248.6 | 184.2 |
| Idarubicin | 5 | 222.4 | 114.5 | 107.9 | 94.3 |
| Ifosfamide | 6 | 493.3 | 172.5 | 320.8 | 186.0 |
| Irinotecan | 29 | 2413.5 | 882.5 | 1531.0 | 173.5 |
| L-asparaginase | 10 | 464.7 | 58.7 | 406.0 | 691.6 |
| Liposomal doxorubicin | 4 | 404.3 | 144.0 | 260.3 | 180.8 |
| Mitomycin-C | 5 | 325.5 | 126.7 | 198.7 | 156.8 |
| Mitoxantrone | 14 | 680.9 | 205.0 | 476.0 | 232.2 |
| Methotrexate | 37 | 3,105.1 | 1,177.0 | 1,928.1 | 163.8 |
| Oxaliplatin | 61 | 4,786.1 | 1,779.0 | 3,007.1 | 169.0 |
| Paclitaxel | 132 | 5,272.8 | 1,561.0 | 3,711.8 | 237.8 |
| Pemetrexed | 8 | 509.5 | 164.5 | 345.0 | 209.7 |
| Vinblastine | 26 | 789.8 | 274.1 | 515.7 | 1,88.1 |
| Vincristine | 91 | 3,079.5 | 175.8 | 2,903.6 | 1,651.2 |
| Vinorelbine | 25 | 1,091.7 | 301.0 | 790.7 | 262.7 |
| Total | 2,250 | 96,273.6 | 29,117.2 | 67,156.4 | 230.6 |
CSTD, closed-system transfer device; MYR, Malaysian Ringgit;
a
Consisting of costs for infusion bottles; luer-lock syringes and the PhaSeal® CSTD;
b
Hypothetical scenario; consisting of costs for infusion bottles;, luer-lock syringes; needles, Mini-Spike® dispensing pins; and Combi-Stopper closing cones;
c
Representing additional costs (MYR and %) incurred by the use of the PhaSeal® CSTD.